Clinical and economic outcomes of adding durvalumab to gemcitabine/cisplatin in advanced biliary tract cancers: A multicenter descriptive study.

Date publication

novembre 2025

Journal

Clinics and research in hepatology and gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Luciani L, Carlier C, Leuk L, Clarenne J, Lepage V, Perrier M, Bouché O, Gigante E, Slimano F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41271098

Résumé

Durvalumab in combination with gemcitabine/cisplatin (GemCis) has expanded therapeutic options for advanced biliary tract cancers (BTCs), raising both clinical and economic considerations. We aim to describe the efficacy, safety and economic impact of durvalumab addition.

Mots clés

Biliary tract cancer, Cisplatin, Durvalumab, Economic impact, Flat-dose, Gemcitabine, Immune checkpoint inhibitor, Weight-based dose;

Référence

Clin Res Hepatol Gastroenterol. 2025 11 19;49(10):102733